A Phase 2 interventional study of CU06-1004 and Placebo Control in DME, Diabetic Macular Edema and Diabetic Macular Edema (DME), sponsored by Curacle Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Curacle Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with Diabetic Macular Edema to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 24 weeks. The study will have a 1:1:1 randomization (CU06-1004 200mg: CU06-1004 300mg: Placebo).
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
This study's planned enrollment of 156 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Curacle Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients will be eligible for inclusion in the study if they meet all of the following criteria:
Exclusion Criteria:
Patients will be excluded from the study if they meet any of the following criteria:
Concurrent and/or history (where indicated) of an ocular condition including one or more of the following in the study eye:
Active proliferative diabetic retinopathy (PDR) or preretinal fibrosis involving the macula.
Note: Patients with mild PDR without high-risk features will be allowed in the study.
Concurrent and/or history (where indicated) of ocular condition including one or more of the following in either eye:
Has the following illness or abnormal laboratory test values:
Has a medical condition that, in the opinion of the investigator, would preclude participation in the study (eg, unstable medical status including blood pressure, cardiovascular disease, and glycemic control or a significant medical condition including end-stage renal disease and severe liver diseases).
Patients with a study eye that meets any of the following criteria may not participate in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral dose of 200 mg CU06-1004 QD (two 100 mg capsules and one placebo capsule)
Drug: CU06-1004
Oral dose of 300 mg CU06-1004 QD (three 100 mg capsules)
Drug: CU06-1004
Oral dose of matching placebo QD (three placebo capsules)
Drug: Placebo Control
CU06-1004 is an oral capsule. At room temperature, it appears as a white to off-white powder. The 100 mg soft gelatin capsules contain a solution-based fill.
Also known as: SAC-1004, CU06, CU06-RE, Riverstat
A matching placebo capsule administered orally
Change of best corrected visual acuity (BCVA)
Mean change in best corrected visual acuity (BCVA) from baseline as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score at Week 24 in the study eye.
Time frame: 24 weeks
Mean change in best corrected visual acuity (BCVA)
Mean change in best corrected visual acuity (BCVA) from baseline as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score at Weeks 4, 8, 12, and 18.
Time frame: Week 4,8,12 and 18
Improvement or worsening rate of Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA)
Improvement or worsening rate of Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA)from baseline: percentage of patients who gained/lost ≥5/10/15 letter score increase of vision in the ETDRS letter score from baseline at each visit.
Time frame: Week 4, 8, 12, 18, 24, and 28
Change in central subfield thickness (CST)
Change in central subfield thickness (CST) in the study eye assessed at each visit by spectral domain optical coherence tomography (SD-OCT) measured by the central reading center (CRC) from baseline
Time frame: Week 4, 8, 12, 18, 24, and 28
Change in all other subfield thickness
Change in all other subfield thickness (nasal, temporal, superior, and inferior) in the study eye from baseline, assessed at each visit by SD-OCT using the ETDRS macular grid (the area between 1 mm to 3 mm and 3 mm to 6 mm by quadrant).
Time frame: Week 4, 8, 12, 18, 24, and 28
Mean change in vessel density (VD) in the superficial capillary plexus (SCP)
Mean change in vessel density (VD) in the superficial capillary plexus (SCP) measured by optical coherence tomography angiography (OCT-A) at Weeks 12 and 24 compared to baseline.
Time frame: Week 12 and 24
Change in ETDRS
Change in ETDRS diabetic retinopathy severity scale (DRSS) at Weeks 12 and 24 as measured by the CRC compared to baseline.
Time frame: Week 12 and 24
Change in inner retinal thickness
Change in inner retinal thickness (internal limiting membrane to other inner nuclear layer) as measured by SD-OCT segmentation and the CRC
Time frame: Week 4, 8, 12, 18, 24, and 28
Change in ganglion cell layer/inner plexiform layer volume
Change in ganglion cell layer/inner plexiform layer volume by OCT macular cube segmentation as measured by the CRC at Weeks 12 and 24 compared to baseline.
Time frame: Week 12 and 24
Change in fluorescein angiography leakage area
Change in fluorescein angiography leakage area at Weeks 12 and 24 compared to baseline as measured by the CRC.
Time frame: Week 12 and 24
Change in choroidal vessel density/area and foveal avascular zone size
Change in choroidal vessel density/area and foveal avascular zone size measured by OCT-A (and CRC) at Weeks 12 and 24 compared to baseline.
Time frame: Week 12 and 24
Percent of patients requiring rescue treatment
Time frame: Week 4, 8, 12, 18, 24, and 28
Change in blood biomarkers
(TNF-alpha, MMP-9, Ang-2, HbA1c, Cystatin-C, vWF, and sTM)
Time frame: Week 12 and 24
Percent change in urinary albumin-to-creatinine ratio and eGFR
Time frame: Week 24
Mean change in vascular perfusion (VP) in the superficial capillary plexus (SCP)
Mean change in vascular perfusion (VP) in the superficial capillary plexus (SCP) measured by optical coherence tomography angiography (OCT-A) at Weeks 12 and 24 compared to baseline.
Time frame: Week 12 and 24
Mean change in vascular perfusion (VP) in the deep capillary plexus (DCP)
Mean change in vascular perfusion (VP) in the deep capillary plexus (DCP)measured by optical coherence tomography angiography (OCT-A) at Weeks 12 and 24 compared to baseline.
Time frame: Week 12 and 24
Mean change in vascular perfusion (VP) in the peripapillary capillary plexus (PCP)
Mean change in vascular perfusion (VP) in the peripapillary capillary plexus (PCP) measured by optical coherence tomography angiography (OCT-A) at Weeks 12 and 24 compared to baseline.
Time frame: Week 12 and 24
Mean change in BCVA
Mean change in BCVA from baseline as measured by ETDRS letters score at each postbaseline visit. - fellow eye
Time frame: Week 4, 8, 12, 18, 24, and 28
Improvement or worsening rate of ETDRS BCVA
Improvement or worsening rate of ETDRS BCVA from baseline: percentage of patients who gained/lost ≥5/10/15 letter score increase of vision in the ETDRS letter score from baseline - fellow eye
Time frame: Week 4, 8, 12, 18, 24, and 28
Change in CST
Change in CST assessed at each visit by SD-OCT measured by CRC from baseline.
Time frame: Week 4, 8, 12, 18, 24, and 28
Change in ETDRS DRSS
Change in ETDRS DRSS at Weeks 12 and 24 measured by CRC compared to baseline. - fellow eye
Time frame: Week 12 and 24
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.
Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's planned 13 months is below that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CU06-1004
Curacle Co., Ltd.